NLS Pharmaceutics AGNASDAQ:NLSPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.1250
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.1250/ 3
- Ask / Lots0.1346/ 48
- Open / Previous Close0.0000 / 0.1250
- Day Range---
- 52 Week Range
- Volume100
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NLSP |
|---|---|---|
| 09:32 ET | 3683 | 0.1299 |
| 10:06 ET | 668 | 0.1291 |
| 10:14 ET | 700 | 0.129 |
| 10:17 ET | 139 | 0.1286 |
| 10:28 ET | 102 | 0.1285 |
| 10:37 ET | 265 | 0.1233 |
| 10:39 ET | 785 | 0.125 |
| 10:44 ET | 2000 | 0.1235 |
| 11:04 ET | 154 | 0.1234 |
| 11:08 ET | 100 | 0.1235 |
| 11:20 ET | 193 | 0.129 |
| 12:20 ET | 100 | 0.1291 |
| 12:27 ET | 133 | 0.129 |
| 12:41 ET | 2015 | 0.12721 |
| 12:43 ET | 100 | 0.129 |
| 01:55 ET | 100 | 0.1291 |
| 02:00 ET | 100 | 0.1268 |
| 02:38 ET | 853 | 0.129 |
| 02:42 ET | 2000 | 0.1275 |
| 03:02 ET | 642 | 0.1283 |
| 03:23 ET | 100 | 0.129 |
| 03:27 ET | 10000 | 0.129 |
| 03:30 ET | 100 | 0.129 |
| 03:36 ET | 3800 | 0.129 |
| 03:43 ET | 5091 | 0.1291 |
| 03:59 ET | 186 | 0.125 |
Apr 19, 2024
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing, from 5:02PM ET on Friday Apr 19, 2024 by Dow Jones
5:02PM ET on Friday Apr 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NLS Pharmaceutics AG | 4.9M | -0.2x | --- |
Portage Biotech Inc | 5.0M | 0.0x | --- |
Synaptogenix Inc | 4.9M | -0.1x | --- |
Alzamend Neuro Inc | 4.9M | -0.3x | --- |
Alterola Biotech Inc | 5.1M | -1.4x | --- |
PaxMedica Inc | 5.2M | 0.0x | --- |
Company Information
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.
Contact Information
- Headquarters
- The Circle 6ZUERICH, Switzerland 8058
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Ronald Hafner
- Chief Executive Officer, Director
- Alexander Zwyer
- Chief Scientific Officer
- Eric Konofal
- Chief Medical Officer and Global Head of Research and Development
- George Apostol
- Independent Director
- Myoung-Ok Kwon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.53 |
Book Value | $0.10 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
